Hemogenyx shares boosted by partner investment
Shares in jumped on Wednesday after the clinical-stage biopharmaceutical group announced another investment from Prevail Partners via a share subscription at a significant premium to the current market value.
Investment fund Prevail Partners agreed to invest $350,000 (£269,000) through a subscription priced at $0.075 (5.6p) per share.
The subscription, which will take effect next March, followed a similar investment by the same fund last month, and comes at a 275% premium to Hemogenyx's closing price of 1.61p on Tuesday.
The investment comes ahead of Hemogenyx's planned HEMO-CAR-T pediatric study, in which Prevail Partners affiliate Prevail InfoWorks will act as clinical research organisation.
"As we seek to bring the curative power of cell therapies to children suffering from the otherwise largely incurable life-threatening diseases, AML and ALL, we are very confident in Prevail InfoWorks' ability to coordinate our Phase I clinical trial in pediatric relapsed/refractory AML and ALL," said Hemogenyx chief executive and co-founder Vladislav Sandler.
"Prevail Partners' strategic investment in the company, once again at a price very substantially above the company's existing share price, demonstrates their confidence in our CAR-T program and in our ability to execute the upcoming clinical study."
The stock was up 5.4% at 1.69p by 1239 BST, briefly surging to a high of 3.0p earlier on.
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.